Table II.

Significant SNPs associated with recurrence in CRC stage II and III patients receiving 5-FU-based adjuvant chemotherapy

SNP	Region (gene)	No recurrence/recurrence	HRb (95% CI)	P value	Log-rank P
Stage II
rs10318	15q13.3 (GREM1)
GG		71/15	1 (Reference)
GA + AA		17/12	2.98 (1.27–6.99)	0.012	0.047
Stage III
rs10749971	11q23.1 (LOC120376, FLJ45803, c11orf53, POU2AF1)
AA		47/19	1 (Reference)
AG		56/21	0.73 (0.36–1.48)	0.382
GG		25/1	0.06 (0.01–0.55)	0.012	0.038
Trend			0.46 (0.27–0.8)	0.006
rs961253b	20p12.3 (BMP2)
CC		50/20	1 (Reference)
CA + AA		79/21	0.46 (0.22–0.96)	0.038	0.201
rs355527b	20p12.3 (BMP2)
GG		57/21	1 (Reference)
GA + AA		71/20	0.48 (0.23–0.99)	0.048	0.360

^aHR adjusted by age, gender, race, tumor location and histology grade.

^bLinkage SNPs.